This page is an unofficial LFoD record and is not legal advice. Verify the document against the official source before relying on it.

HB159: adding fibromyalgia to qualifying medical conditions under therapeutic use of cannabis.

Bill details

Version history, amendments, and roll-call votes were not present in the imported local bill data.

Sponsors

Topics

Health care Cannabis

Official links

HB 159 - AS INTRODUCED

2017 SESSION

17-0116

01/09

HOUSE BILL 159

AN ACT adding fibromyalgia to qualifying medical conditions under therapeutic use of cannabis.


ANALYSIS

This bill adds fibromyalgia to the qualifying medical conditions under therapeutic use of cannabis.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

17-0116

01/09

STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Seventeen

AN ACT adding fibromyalgia to qualifying medical conditions under therapeutic use of cannabis.

Be it Enacted by the Senate and House of Representatives in General Court convened:

1 Use of Cannabis for Therapeutic Purposes; Definitions. Amend RSA 126-X:1, IX(a)(1) to read as follows:

(1) Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C currently receiving antiviral treatment, amyotrophic lateral sclerosis, muscular dystrophy, Crohn's disease, multiple sclerosis, chronic pancreatitis, spinal cord injury or disease, traumatic brain injury, epilepsy, lupus, Parkinson's disease, Alzheimer's disease, ulcerative colitis, fibromyalgia, or one or more injuries that significantly interferes with daily activities as documented by the patient's provider; and

2 Effective Date. This act shall take effect 60 days after its passage.